Parenteral formulation

Details Parenteral formulation Parenteral formulation

1985-07-23

1986-08-12

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

A61U 31135

Patent

active

046056718

ABSTRACT:
Ready-to-use parenteral formulations of Dezocine containing from about 0.2 to about 2.0 percent wt/vol. Dezocine; about 30 to about 45 percent wt/vol. propylene glycol; about 0.5 to about 2.0 percent wt/vol. lactic acid buffered with a pharmaceutically acceptable base to a pH of from about 3.5 to about 5.0 and 0 to 0.02 percent wt/vol. sodium metabisulfite, in water for injection.

REFERENCES:
Merck Index, 9th Ed (1976) 1017.
Remington's Pharmaceutical Science 16th ed (1980), pp. 1225-1227, 700-701.
Oosterlinck et al., Curr. Med. Res. Opin. 6 472-474, (1980).
Staquet, Curr. Med. Res-Opin. 6 634-637, (1980).
Molis et al., J. Pharmacol Exp. Ther. 194, 488-498, .COPYRGT.1975.

Affiliated with

Also associated with

Rating

Parenteral formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Parenteral formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1935727